

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **JOINN LABORATORIES (CHINA) CO., LTD.**

### **北京昭衍新藥研究中心股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 6127)**

## **2024 THIRD QUARTERLY REPORT**

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the third quarterly report of JOINN Laboratories (China) Co., Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) for financial year 2024 (the “**2024 Third Quarterly Report**”). This announcement and the accompanying financial statements are originally prepared in Chinese and published in both English and Chinese. If there is any inconsistency or conflict between the Chinese and English versions, the Chinese version shall prevail.

Shareholders of the Company and public investors should note that the financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and has not been audited.

By Order of the Board  
**JOINN Laboratories (China) Co., Ltd.**  
**Feng Yuxia**  
*Chairperson*

Beijing, the PRC, 30 October 2024

*As at the date of this announcement, the Board comprises Ms. Feng Yuxia as the Chairperson and executive Director, Mr. Zuo Conglin, Mr. Gao Dapeng and Ms. Sun Yunxia as executive Directors, and Mr. Sun Mingcheng, Dr. Zhai Yonggong, Mr. Ou Xiaojie and Mr. Zhang Fan as independent non-executive Directors.*

## IMPORTANT NOTICE

The board of Directors, the Supervisory Committee, the Directors, Supervisors and senior management of the Company warrant that the information stated in this quarterly report is true, accurate, complete and without any false representation, misleading statement or material omission, and assume several and joint liabilities.

The person in charge of the Company, the person in charge of accounting affairs, and the person responsible for the accounting department (head of the accounting department), hereby warrant the truthfulness, accuracy and completeness of the financial statements contained in this quarterly report.

Whether the third quarterly report has been audited

Yes  No

### I. MAJOR FINANCIAL DATA

#### (I) Key accounting data and financial indicators

Unit: RMB Currency: RMB

Item	Reporting Period	Change during the Reporting Period compared to the same period of last year (%)	From the beginning of the year to the end of the Reporting Period	Change from the beginning of the year to the end of the Reporting Period compared to the same period of last year (%)
Revenue	485,799,506.29	-15.51	1,335,156,050.40	-15.87
Net profit attributable to shareholders of the listed company	99,435,565.54	-58.04	-70,307,075.11	-121.46
Net profit attributable to shareholders of the listed company after deducting non-recurring gain or loss items	84,926,745.33	-63.74	-113,468,202.36	-136.47
Net cash flow from operating activities	N/A	N/A	192,325,709.34	-57.11
Basic earnings per share (RMB per share)	0.13	-59.38	-0.09	-120.45
Diluted earnings per share (RMB per share)	0.13	-59.38	-0.09	-120.45
Weighted average return on net assets (%)	1.22	Decreased by 1.66 percentage points	-0.86	Decreased by 4.84 percentage points
	At the end of the Reporting Period		At the end of last year	Change as compared to the end of last year (%)
Total assets	9,525,184,807.98		10,027,159,630.47	-5.01
Owners' equity attributable to shareholders of the listed company	8,002,435,682.20		8,279,315,724.35	-3.34

Note: The "Reporting Period" refers to the three-month period from the beginning of this quarter to the end of this quarter, the same shall apply below.

## Description of key accounting data and financial indicators of the Company

The net profit attributable to shareholders of the listed company after deducting non-recurring gain or loss items is primarily affected by the profit incurred in the laboratory services business and the fund management income, as well as the fluctuation in market prices of biological assets.

- 1) The laboratory services business incurred a net profit of RMB-1,705,100 from the beginning of the year to the end of the Reporting Period, representing a year-on-year decrease of 100.55% (corresponding period of last year: RMB308,862,700), which was mainly attributable to intensified competition and decline in gross profit margin.
- 2) The fund management income generated a net profit of RMB65,221,100 from the beginning of the year to the end of the Reporting Period.
- 3) The change in fair value of biological assets incurred a net loss of RMB176,984,200 from the beginning of the year to the end of the Reporting Period.

Note: Net profit from laboratory services business: the net profit attributable to the shareholders of the listed company after deducting non-recurring gain or loss items, eliminating the impact of gain or loss from change in fair value of biological assets and interest income and foreign exchange gain or loss.

## (II) Non-recurring profit or loss items and amounts

✓ Applicable     Not applicable

Unit: RMB    Currency: RMB

Non-recurring profit or loss items	Amount for the period	Amount from the beginning of the year to the end of the Reporting Period	Description
Gain or loss on disposal of non-current assets (including the write-off portion of the provision for asset impairment recognized)	-20,541.19	-575,676.73	
Government grants included in profit or loss of the current period, except for those closely related to the Company's normal operation, granted in accordance with national policies and prescribed standards and affecting the Company's profit or loss account on an ongoing basis	9,552,973.56	18,454,523.55	
Profit or loss arising from changes in the fair value of financial assets and financial liabilities held by non-financial enterprises and profit or loss arising from disposal of financial assets and financial liabilities, except for effective hedging business related to normal operating of the Company	7,283,222.47	17,081,720.48	

<b>Non-recurring profit or loss items</b>	<b>Amount for the period</b>	<b>Amount from the beginning of the year to the end of the Reporting Period</b>	<b>Description</b>
Capital occupancy fees from non-financial enterprises recognized through profit or loss for the period			
Gain or loss from entrusted investments or assets management			
Profit or loss from external entrusted loans			
Asset losses caused by force majeure (such as natural disasters)			
Reversal of provision for impairment of receivables subject to impairment test separately			
Gain from the difference between the cost of investment on the subsidiaries, associates and joint ventures and the shared fair value of identifiable net assets of the investee			
Net profit or loss of subsidiaries resulting from merger of enterprises under common control from the beginning of the current period to the date of merger			
Profit or loss from exchange of non-monetary assets			
Profit or loss from debt restructuring			
One-off expenses incurred due to discontinuation of relevant operation activities (such as staff resettlement expenses)			
One-off effect on profit or loss of the current period due to adjustments of taxation and accounting laws and regulations			

<b>Non-recurring profit or loss items</b>	<b>Amount for the period</b>	<b>Amount from the beginning of the year to the end of the Reporting Period</b>	<b>Description</b>
Share-based payment expenses recognized on the one-off basis due to cancellation or revision of the equity incentive plan			
Profit or loss from changes in the fair value of employee benefit payables after the vesting date (in respect of share-based payment settled by cash)			
Profit or loss from changes in fair value of investment properties using the fair value model for subsequent measurement			
Gain from the transaction at an unfair price			
Profit or loss from contingencies not related to the ordinary operations of the Company			
Fees income from custodian business			
Other non-operating incomes and expenses other than the above items	-14,348.87	-124,253.18	
Other profit or loss items falling within the meaning of non-recurring profit or loss		15,471,314.63	
Less: Effect of income tax	-2,292,485.76	-7,146,501.50	
Effect on interest of minority shareholders (after tax)			
Total	14,508,820.21	43,161,127.25	

Information on the designation of items not listed in “Explanatory Announcement No. 1 on Disclosure of Information by Companies with Publicly Issued Securities – Non-recurring Profit or Loss” as non-recurring profit or loss items of significant amount and the classification of non-recurring profit or loss items listed in “Explanatory Announcement No. 1 on Disclosure of Information by Companies with Publicly Issued Securities – Non-recurring Profit or Loss” as recurring profit or loss items, with relevant reasons provided.

Applicable     Not applicable

**(III) Changes in key accounting data and financial indicators and reasons for such changes**

✓ Applicable    □ Not applicable

Items	Change (%)	Main reason
Net profit attributable to shareholders of the listed company_from the beginning of the year to the end of the Reporting Period	-121.46	Mainly due to the intensified competition from the beginning of the year to the end of the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin and the fair value of biological assets
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss items_from the beginning of the year to the end of the Reporting Period	-136.47	Mainly due to the intensified competition from the beginning of the year to the end of the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin and the fair value of biological assets
Net cash flow from operating activities_from the beginning of the year to the end of the Reporting Period	-57.11	Mainly due to the decrease in sales proceeds from the beginning of the year to the end of the Reporting Period, while the amount of the paid employee remuneration was basically unchanged compared to the corresponding period of last year
Basic earnings per share_from the beginning of the year to the end of the Reporting Period	-120.45	Mainly due to the intensified competition from the beginning of the year to the end of the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin and the fair value of biological assets
Diluted earnings per share_from the beginning of the year to the end of the Reporting Period	-120.45	Mainly due to the intensified competition from the beginning of the year to the end of the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin and the fair value of biological assets
Net profit attributable to shareholders of the listed company_the Reporting Period	-58.04	Mainly due to the intensified competition during the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin
Net profit attributable to shareholders of the listed company after deducting non-recurring profit or loss items_the Reporting Period	-63.74	Mainly due to the intensified competition during the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin
Basic earnings per share_the Reporting Period	-59.38	Mainly due to the intensified competition during the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin
Diluted earnings per share_the Reporting Period	-59.38	Mainly due to the intensified competition during the Reporting Period, which resulted in a decrease in sales revenue and gross profit margin

## II. INFORMATION OF SHAREHOLDERS

### (I) Statement of the total number of holders of ordinary shares and holders of preference shares with restored voting rights, and the particulars of shareholdings of the top 10 shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the Reporting Period	72,246	Total number of holders of preference shares with restored voting rights as at the end of the Reporting Period (if any)	0			
<b>Shareholding of top 10 shareholders (excluding shares lent under the refinancing and securities lending arrangement)</b>						
Name of shareholder	Nature of shareholder	Number of shares held	Percentage of shareholding (%)	Number of Shares subject to trading restrictions	Shares pledged, marked or frozen	
					Status of shares	Number of shares
Feng Yuxia	Domestic natural person	167,160,633	22.30	0	Nil	0
HKSCC NOMINEES LIMITED	Overseas legal person	118,974,786	15.87	0	Nil	
Zhou Zhiwen	Domestic natural person	74,725,981	9.97	0	Nil	0
Gu Xiaolei	Domestic natural person	20,420,504	2.72	0	Pledged	9,604,000
Zuo Conglin	Domestic natural person	14,098,317	1.88	0	Nil	0
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	Others	12,824,484	1.71	0	Nil	0
Gu Meifang	Domestic natural person	10,322,035	1.38	0	Pledged	8,400,000
Hong Kong Securities Clearing Company Limited	Overseas legal person	9,071,437	1.21	0	Nil	0
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	Others	7,294,029	0.97	0	Nil	0
Agricultural Bank of China Limited – CSI 500 Trading Open-ended Index Securities Investment Fund	Others	6,079,475	0.81	0	Nil	0

<b>Shareholdings of top 10 holders of shares not subject to trading restrictions (excluding shares lent under the refinancing and securities lending arrangement)</b>			
<b>Name of shareholder</b>	<b>Number of shares not subject to trading restrictions</b>	<b>Class and number of shares</b>	
		<b>Class of shares</b>	<b>Number of shares</b>
Feng Yuxia	167,160,633	RMB-denominated ordinary shares	167,160,633
HKSCC NOMINEES LIMITED	118,974,786	Overseas-listed foreign shares	118,974,786
Zhou Zhiwen	74,725,981	RMB-denominated ordinary shares	74,725,981
Gu Xiaolei	20,420,504	RMB-denominated ordinary shares	20,420,504
Zuo Conglin	14,098,317	RMB-denominated ordinary shares	14,098,317
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	12,824,484	RMB-denominated ordinary shares	12,824,484
Gu Meifang	10,322,035	RMB-denominated ordinary shares	10,322,035
Hong Kong Securities Clearing Company Limited	9,071,437	RMB-denominated ordinary shares	9,071,437
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	7,294,029	RMB-denominated ordinary shares	7,294,029
Agricultural Bank of China Limited – CSI 500 Trading Open-ended Index Securities Investment Fund	6,079,475	RMB-denominated ordinary shares	6,079,475
Description of related party relationships or concerted actions of the above shareholders	1. Feng Yuxia and Zhou Zhiwen are in a spousal relationship; 2. Gu Meifang and Gu Xiaolei are aunt and nephew. Except from this, the Company is not aware of any related party relationship among the shareholders mentioned above, and not aware of whether they are parties acting in concert.		
Description of top 10 shareholders and top 10 shareholders not subject to trading restrictions participating in margin trading and refinancing business (if any)	Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund, Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund and Agricultural Bank of China Limited – CSI 500 Trading Open-ended Index Securities Investment Fund have involved in the refinancing business, whereas the other top 10 shareholders have not participated in any of such activities.		



Information of shares lent under the refinancing and securities lending arrangement in which shareholders owning over 5% equity, top 10 shareholders and top 10 shareholders not subject to trading restrictions have involved

✓ Applicable    □ Not applicable

Unit: Share

Shares lent under the refinancing and securities lending arrangement in which shareholders owning over 5% equity, top 10 shareholders and top 10 shareholders not subject to trading restrictions have involved								
Full name of shareholder	Shares held under the general account and credit account at the beginning of Reporting Period		Shares lent under the refinancing arrangement but not returned at the beginning of Reporting Period		Shares held under the general account and credit account at the end of Reporting Period		Shares lent under the refinancing arrangement but not returned at the end of Reporting Period	
	Total number	Proportion (%)	Total number	Proportion (%)	Total number	Proportion (%)	Total number	Proportion (%)
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	10,850,564	1.45	494,600	0.07	12,824,484	1.71	0	0
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	7,435,989	0.99	169,100	0.02	7,294,029	0.97	0	0
Agricultural Bank of China Limited – CSI 500 Trading Open-ended Index Securities Investment Fund	1,997,979	0.27	613,900	0.08	6,079,475	0.81	0	0

Change in the Reporting Period (as compared to the same period of last year) due to the lending/return of shares under the refinancing arrangement by top 10 shareholders and top 10 shareholders not subject to trading restrictions

Applicable    Not applicable

Unit: Share

Change in the Reporting Period (as compared to the same period of last year) due to the lending/return of shares under the refinancing arrangement by top 10 shareholders and top 10 shareholders not subject to trading restrictions					
Full name of shareholder	Addition/ withdrawal in the Reporting Period	Shares lent under the refinancing arrangement but not returned at the end of Reporting Period		Shares held under the general account and credit account, and lent under the refinancing arrangement but not returned at the end of Reporting Period	
		Total number	Proportion (%)	Total number	Proportion (%)
Bank of China Limited – Huabao CSI Medical Trading Open-ended Index Securities Investment Fund	Withdrawal	0	0	12,824,484	1.71
Bank of China Limited – China Merchants National Securities Biomedical Index Classified Securities Investment Fund	Withdrawal	0	0	7,294,029	0.97
Agricultural Bank of China Limited – CSI 500 Trading Open-ended Index Securities Investment Fund	Withdrawal	0	0	6,079,475	0.81

### III. OTHER MATTERS REQUIRED ATTENTION

Other important information on the Company's operation during the Reporting Period that needs to be brought to the attention of investors

Applicable    Not applicable

Owing to the combined effect of multiple factors, new orders of the Group were totalling approximately RMB1.4 billion during the first three quarters. As at the end of the Reporting Period, the Company had orders of approximately RMB2.65 billion as a whole. The execution of orders was affected by multiple factors. Investors are advised to exercise caution when dealing in shares of the Company.

### IV. QUARTERLY FINANCIAL STATEMENTS

#### (I) Type of audit opinion

Applicable    Not applicable

**(II) Financial statements****Consolidated Balance Sheet**

30 September 2024

Prepared by: JOINN Laboratories (China) Co., Ltd.

Unit: RMB Currency: RMB Type of audit: Unaudited

Item	30 September 2024	31 December 2023
<b>Current assets:</b>		
Monetary fund	1,840,124,511.87	2,862,911,984.90
Provision of settlement fund		
Funds lent		
Financial assets held for trading	1,382,197,887.15	373,354,146.08
Derivative financial assets		
Bills receivables	15,521,997.90	6,873,300.00
Account receivables	213,041,670.24	206,014,475.30
Receivables financing		
Prepayments	93,367,592.03	110,147,213.48
Premium receivables		
Reinsurance account receivables		
Deposit receivables from reinsurance contracts		
Other receivables	11,307,419.49	11,507,653.51
Including: Interest receivables		
Dividend receivables		
Financial assets purchased under agreements to resell		
Inventories	1,631,793,427.45	1,863,081,944.56
Including: Data resources		
Contract assets	101,229,555.78	127,171,761.27
Assets held-for-sale		
Non-current assets due within one year		1,533,490,014.42
Other current assets	45,527,967.05	27,414,846.59
Total current assets	5,334,112,028.96	7,121,967,340.11

Item	30 September 2024	31 December 2023
<b>Non-current assets:</b>		
Loans and advances to customers		
Debt investment		
Other debt investment		
Long-term receivables		
Long-term equity investments		19,528,685.37
Investments in other equity instruments	159,840,000.00	159,840,000.00
Other non-current financial assets	614,027,609.91	587,783,644.59
Investment properties		
Fixed assets	669,976,461.06	583,318,976.70
Construction in progress	323,645,798.21	342,008,170.08
Biological assets for breeding	393,069,851.01	558,873,617.05
Oil and gas assets		
Right-of-use assets	64,522,594.94	63,450,726.95
Intangible assets	294,064,206.17	292,379,829.73
Including: Data resources		
Development expenses		
Including: Data resources		
Goodwill	134,561,113.99	136,007,078.53
Long-term deferred expenditures	67,282,378.50	74,889,044.45
Deferred tax assets	39,181,770.56	28,251,272.62
Other non-current assets	1,430,900,994.67	58,861,244.29
Total non-current assets	4,191,072,779.02	2,905,192,290.36
Total assets	9,525,184,807.98	10,027,159,630.47
<b>Current liabilities:</b>		
Short-term borrowings		
Borrowings from central bank		
Funds borrowed		
Financial liabilities held for trading		
Derivative financial liabilities		
Bills payables		
Account payables	39,305,320.91	43,323,313.28

<b>Item</b>	<b>30 September 2024</b>	<b>31 December 2023</b>
Receipts in advance		
Contract liabilities	1,064,046,398.38	1,151,973,539.70
Financial assets sold under agreements to repurchase		
Deposits from customers and banks		
Customer deposits for securities trading		
Customer deposits for securities underwriting		
Employee benefit payables	82,520,776.76	106,582,526.14
Tax payables	8,611,739.52	44,600,630.06
Other payables	62,202,411.21	88,992,348.61
Including: Interest payables		
Dividend payables		
Handling charges and commission payable		
Reinsurance account payables		
Liabilities held-for-sale		
Non-current liabilities due within one year	38,697,752.54	27,499,926.74
Other current liabilities	3,322,471.24	4,392,804.11
Total current liabilities	1,298,706,870.56	1,467,365,088.64
<b>Non-current liabilities:</b>		
Deposits for insurance contracts		
Long-term borrowings		
Debenture payables		
Including: Preference shares		
Perpetual bonds		
Lease liabilities	32,771,963.22	41,924,537.74
Long-term payables		
Long-term payroll payables		
Projected liabilities		
Deferred income	69,616,218.99	74,487,463.86
Deferred tax liabilities	133,255,156.98	162,342,125.15
Other non-current liabilities		
Total non-current liabilities	235,643,339.19	278,754,126.75
Total liabilities	1,534,350,209.75	1,746,119,215.39

<b>Item</b>	<b>30 September 2024</b>	<b>31 December 2023</b>
<b>Owners' equity (or shareholders' equity):</b>		
Paid up capital (or share capital)	749,477,334.00	749,888,699.00
Other equity instruments		
Including: Preference shares		
Perpetual bonds		
Capital reserves	5,250,020,019.41	5,267,128,243.75
Less: Treasury shares	211,100,000.16	146,450,061.16
Other comprehensive income	95,658,951.64	100,518,137.39
Special reserve		
Surplus reserve	144,259,244.76	144,259,244.76
General risks reserve		
Retained earnings	1,974,120,132.55	2,163,971,460.61
Total owners' equity (or shareholders' equity) attributable to the parent company	8,002,435,682.20	8,279,315,724.35
Non-controlling interests	-11,601,083.97	1,724,690.73
Total owners' equity (or shareholders' equity)	7,990,834,598.23	8,281,040,415.08
Total liabilities and owners' equity (or shareholders' equity)	9,525,184,807.98	10,027,159,630.47

*Legal Representative:*  
**Feng Yuxia**

*Chief Financial Officer:*  
**Yu Aishui**

*Director of the  
Accounting Department:*  
**Yu Aishui**

**Consolidated Income Statement**  
January to September 2024

Prepared by: JOINN Laboratories (China) Co., Ltd.

Unit: RMB    Currency: RMB    Type of audit: Unaudited

Item	First three quarters of 2024 (January to September)	First three quarters of 2023 (January to September)
<b>I. Total revenue</b>	1,335,156,050.40	1,587,079,779.38
Including: Operating Revenue	1,335,156,050.40	1,587,079,779.38
Interest income		
Premiums earned		
Handling charges and commission income		
<b>II. Total cost</b>	1,227,734,251.03	1,104,837,171.01
Including: Operating Cost	968,251,629.50	892,455,550.25
Interest expenses		
Handling charges and commission expenses		
Payments on surrender		
Net claim expenses		
Net provision for insurance contract reserves		
Policyholder dividend expenses		
Reinsurance costs		
Taxes and surcharges	6,894,612.65	5,740,849.91
Selling expenses	19,402,507.49	18,332,633.83
Administration expenses	236,735,760.07	229,236,753.25
Research and development expenses	71,085,657.06	77,639,680.27
Finance expenses	-74,635,915.74	-118,568,296.50
Including: Interest expense	1,827,953.64	2,425,988.17
Interest income	82,526,990.66	108,316,598.07

<b>Item</b>	<b>First three quarters of 2024 (January to September)</b>	<b>First three quarters of 2023 (January to September)</b>
Add: Other income	19,124,400.35	19,887,566.02
Investment gains (“-” indicating loss)	31,620,189.62	7,141,662.72
Including: Gains from investment in associates and joint ventures	15,471,314.63	-2,553,095.99
Derecognition of income from financial assets measured at amortised cost		
Exchange gains (“-” indicating loss)		
Gains from net exposure to hedging (“-” indicating loss)		
Gains from changes in fair value (“-” indicating loss)	-190,401,449.68	-108,513,934.09
Credit impairment losses (“-” indicating loss)	-11,477,062.92	-3,187,147.18
Assets impairment losses (“-” indicating loss)	-25,480,216.62	-5,418,844.22
Gains from disposal of assets (“-” indicating loss)	-468,673.84	-66,971.62
<b>III. Operating profit (“-” indicating loss)</b>	<b>-69,661,013.72</b>	<b>392,084,940.00</b>
Add: Non-operating income	96,166.74	235,928.52
Less: Non-operating expenses	327,422.81	335,688.11
<b>IV. Profits before income tax (“-” indicating total losses)</b>	<b>-69,892,269.79</b>	<b>391,985,180.41</b>
Less: Income tax expenses	4,351,740.15	65,788,177.76
<b>V. Net profits (“-” indicating net loss)</b>	<b>-74,244,009.94</b>	<b>326,197,002.65</b>
(I) Classified by the continuity of operation		
1. Net profit from continuing operations (“-” indicating net loss)	-74,244,009.94	326,197,002.65
2. Net profit from discontinued operations (“-” indicating net loss)		
(II) Classified by the ownership		
1. Net profit attributable to equity shareholders of the parent (“-” indicating net loss)	-70,307,075.11	327,598,359.05
2. Profit and loss of non-controlling interests (“-” indicating net loss)	-3,936,934.83	-1,401,356.40



<b>Item</b>	<b>First three quarters of 2024 (January to September)</b>	<b>First three quarters of 2023 (January to September)</b>
<b>VI. Other comprehensive income, net of tax</b>	-4,859,185.75	10,184,198.02
(I) Other comprehensive income attributable to owners of the parent company, net of tax	-4,859,185.75	10,184,198.02
1. Other comprehensive income that will not be reclassified to profit or loss		
(1) Changes in re-measurement of defined benefit plans		
(2) Other comprehensive income that will not be transferred to profit or loss accounted for using equity method		
(3) Changes in fair value of investments in other equity instruments		
(4) Changes in fair value of the company's own credit risk		
2. Other comprehensive income that will be reclassified to profit or loss	-4,859,185.75	10,184,198.02
(1) Other comprehensive income that will be transferred to profit or loss accounted for using equity method		
(2) Changes in fair value of other debt investments		
(3) Financial assets reclassified to other comprehensive income		
(4) Credit impairment allowance of other debt investments		
(5) Cash flow hedging reserve		
(6) Exchange difference on translation of foreign financial statements	-4,859,185.75	10,184,198.02
(7) Others		
(II) Other comprehensive income attributable to minority shareholders, net of tax		

<b>Item</b>	<b>First three quarters of 2024 (January to September)</b>	<b>First three quarters of 2023 (January to September)</b>
<b>VII. Total comprehensive income</b>	-79,103,195.69	336,381,200.67
(I) Total comprehensive income attributable to equity shareholders of the parent company	-75,166,260.86	337,782,557.07
(II) Total comprehensive income attributable to non-controlling interests	-3,936,934.83	-1,401,356.40
<b>VIII. Earnings per share:</b>		
(I) Basic earnings per share (RMB per share)	-0.09	0.44
(II) Diluted earnings per share (RMB per share)	-0.09	0.44

For the business combination involving enterprises under common control during the Reporting Period, realised net profit of the merged parties before the merger was RMB0 (corresponding period of the previous year: RMB0).

*Legal Representative:*  
**Feng Yuxia**

*Chief Financial Officer:*  
**Yu Aishui**

*Director of the  
Accounting Department:*  
**Yu Aishui**

**Consolidated Cash Flow Statement**  
January to September 2024

Prepared by: JOINN Laboratories (China) Co., Ltd.

Unit: RMB    Currency: RMB    Type of audit: Unaudited

Item	First three quarters of 2024 (January to September)	First three quarters of 2023 (January to September)
<b>I. Cash flows from operating activities:</b>		
Cash received from the sale of goods and rendering of services	1,302,922,496.39	1,797,650,008.92
Net increase in deposits from customers and placements from bank and other financial institutions		
Net increase in borrowings from central bank		
Net increase in borrowings from other financial institutions		
Cash received from premiums of original insurance contracts		
Net cash received from reinsurance operations		
Net increase in policyholders' deposits and investments		
Cash received from interest, handling charges and commission		
Net increase in loans from banks and other financial institutions		
Net increase in capital for repurchase		
Net cash received from securities trading agency services		
Refund of taxes and surcharges	3,633,470.76	2,002,668.82
Cash received from other operating activities	61,135,423.58	74,478,323.27
Sub-total of cash inflow from operating activities	1,367,691,390.73	1,874,131,001.01
Cash paid for goods purchased and service rendered	450,455,951.77	660,363,395.23
Net increase in loans and advances to customers		
Net increase in placements with central bank and other financial institutions		
Cash paid for claims on original insurance contracts		
Net increase in loans to banks and other financial institutions		

<b>Item</b>	<b>First three quarters of 2024 (January to September)</b>	<b>First three quarters of 2023 (January to September)</b>
Cash paid for interest, handling charges and commission		
Cash paid for policyholders' dividend		
Cash paid to and on behalf employees	531,824,473.43	540,974,402.03
Taxes paid	108,325,574.33	143,674,414.28
Cash paid for other operating activities	84,759,681.86	80,678,571.05
Sub-total of cash outflow from operating activities	1,175,365,681.39	1,425,690,782.59
Net cash flow from operating activities	192,325,709.34	448,440,218.42
<b>II. Cash flow from investing activities:</b>		
Cash received from disposal of investments	2,307,885,508.22	501,496,756.80
Cash received from returns on investment	190,456,675.35	22,623,640.61
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	555,931.64	101,405.63
Net cash received from disposal of subsidiaries and other business entities		
Cash received from other investing activities	9,200,000.00	4,417,661.10
Sub-total of cash inflow from investing activities	2,508,098,115.21	528,639,464.14
Cash paid to acquire fixed assets, intangible assets and other long-term assets	188,019,727.66	149,651,195.84
Cash paid to acquire investments	3,270,129,154.26	426,076,500.00
Net increase in pledged loans		
Net cash paid for acquisition of subsidiaries and other business entities		90,059,524.17
Cash paid for other investing activities		
Sub-total of cash outflow from investing activities	3,458,148,881.92	665,787,220.01
Net cash flow from investing activities	-950,050,766.71	-137,147,755.87

Item	First three quarters of 2024 (January to September)	First three quarters of 2023 (January to September)
<b>III. Cash flow from financing activities:</b>		
Cash received from capital contributions		
Including: Cash received from capital contribution by minority shareholders of subsidiaries		
Cash received from borrowings		
Cash received relating to other financing activities		
Sub-total of cash inflow from financing activities		
Cash repayments of borrowings		6,873,351.14
Cash payments for distribution of dividends, profits or interest expenses	119,633,363.20	214,330,468.72
Including: Dividends and profits paid by subsidiaries to non-controlling interests		
Cash payments relating to other financing activities	129,194,728.77	112,085,377.89
Sub-total of cash outflow from financing activities	248,828,091.97	333,289,197.75
Net cash flow from financing activities	-248,828,091.97	-333,289,197.75
<b>IV. Effect of foreign exchange rate changes on cash and cash equivalents</b>	-6,969,366.76	13,801,951.60
<b>V. Net increase in cash and cash equivalents</b>	-1,013,522,516.10	-8,194,783.60
Add: Cash and cash equivalents at the beginning of the period	2,853,647,027.97	2,899,469,580.53
<b>VI. Cash and cash equivalents at the end of the period</b>	1,840,124,511.87	2,891,274,796.93

*Legal Representative:*  
**Feng Yuxia**

*Chief Financial Officer:*  
**Yu Aishui**

*Director of the  
Accounting Department:*  
**Yu Aishui**

Adjustments to financial statements at the beginning of the year upon initial adoption of new accounting standards or interpretation of standards since 2024

Applicable     Not applicable

This announcement is hereby made.

Board of Directors of JOINN Laboratories (China) Co., Ltd.  
30 October 2024